A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Prostate-Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Positive Hormone-Sensitive Prostate Cancer Participants (PRIMORDIUM)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04557059 |
|
Recruitment Status :
Recruiting
First Posted : September 21, 2020
Last Update Posted : June 21, 2022
|
Sponsor:
Janssen Pharmaceutica N.V., Belgium
Information provided by (Responsible Party):
Janssen Pharmaceutica N.V., Belgium
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | January 14, 2028 |
| Estimated Study Completion Date : | January 14, 2028 |